Personalis Inc., a company operating within the health care sector, is headquartered in Menlo Park, United States. The firm specializes in genomic sequencing and analytics solutions, focusing on the development of personalized cancer vaccines and next-generation cancer immunotherapies. Personalis Inc. serves a global customer base and is listed on the Nasdaq stock exchange.
As of October 12, 2026, Personalis Inc.’s share price closed at $15.85. The company’s stock has experienced fluctuations over the past year, with a 52-week high of $18.89 recorded on August 20, 2026, and a 52-week low of $4.955 on April 28, 2026. The market capitalization of Personalis Inc. stands at approximately $1.69 billion USD.
Recent trading activity has seen a modest decline in Personalis Inc.’s share price, attributed to institutional investors adjusting their holdings. Notably, a major exchange-traded fund managed by ARK Invest reduced its stake in Personalis Inc. This reduction is part of a broader portfolio rebalancing strategy, shifting focus from Personalis Inc. to other biotechnology companies. Despite this, the sale did not induce significant market volatility, indicating a stable trading environment for Personalis Inc.
The company’s price-to-earnings ratio is currently at -14.42, reflecting the challenges and uncertainties often associated with biotechnology firms, particularly those in the early stages of developing innovative therapies. Despite these challenges, Personalis Inc. continues to maintain a stable position in the market, with its share price movements aligning with broader trends of gradual portfolio adjustments rather than any dramatic market events.
Personalis Inc. remains committed to advancing its mission of providing cutting-edge genomic solutions to support personalized medicine. For more information on their services and initiatives, interested parties can visit their website at www.personalis.com .
